Omnicell (NASDAQ:OMCL) Upgraded to Buy at StockNews.com

Omnicell (NASDAQ:OMCL) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

OMCL has been the subject of several other reports. JPMorgan Chase & Co. cut their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Wells Fargo & Company lowered their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Bank of America dropped their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Finally, Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Performance

OMCL opened at $30.95 on Tuesday. The business has a fifty day simple moving average of $35.74 and a 200-day simple moving average of $41.45. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.45 billion, a PE ratio of 114.63, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities analysts predict that Omnicell will post 1.09 EPS for the current fiscal year.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after buying an additional 28,573 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock valued at $73,127,000 after acquiring an additional 394,820 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after purchasing an additional 737,536 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after acquiring an additional 377,883 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after purchasing an additional 699,925 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.